Variational AI is a Vancouver company, founded in 2019, that uses generative AI to design new small-molecule drugs. Its Enki platform generates novel, optimized molecules for a given target, with the aim of cutting early drug discovery from years to months.
The company has a collaboration with Merck and, in 2026, received provincial health testbed funding with 3C Therapeutics to apply its platform to cancer treatments.